Blood vessel complications after leg artery procedures with SGLT2 inhibitors
Part of Heart & circulation clinical trials.
This study looks at how a type of medicine called SGLT2 inhibitors (used for diabetes, kidney disease, or heart issues) affects blood vessel complications in people who have had a leg procedure to improve blood flow. It compares patients taking the medicine to those who are not.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having or have had a procedure (surgery or a minimally invasive procedure) on a leg blood vessel to restore blood flow because of poor circulation.
- You are taking a type of medicine called an SGLT2 inhibitor (names often end in -flozin, like empagliflozin) for at least 3 months before the procedure, or you start taking it right after the procedure.
- You can be checked on for at least 30 days and up to 1 year after the procedure to see how you are doing.
- Your procedure was not for an injury.
- You do not have any other planned surgeries at the time you leave the hospital that involve high-risk procedures (like heart surgery or another amputation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving certain blood-thinning medicines after a leg artery procedure helps prevent serious problems like heart attacks or strokes. It compares different treatment plans to see which is safer and more effective.
This study looks at a protein on immune cells in the blood of people with advanced peripheral artery disease (narrowed leg arteries). It is a first step toward testing a new class of drugs (GLP-1 receptor agonists) to help people with severe leg circulation problems.
This study looks at results of a minimally invasive procedure done inside blood vessels (endovascular therapy) for people with painful or worsening leg artery disease. It uses both past (retrospective) and future (prospective) patient information to better understand outcomes.
This study is testing whether a class of diabetes medicines called SGLT2 inhibitors (specifically empagliflozin or dapagliflozin) can prevent kidney injury after heart procedures that use contrast dye.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
Hear when a new Peripheral Arterial Disease(PAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.